GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Short-Term Debt

Fennec Pharmaceuticals (TSX:FRX) Short-Term Debt : C$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Short-Term Debt?

Fennec Pharmaceuticals's Short-Term Debt for the quarter that ended in Dec. 2023 was C$0.00 Mil.

Fennec Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for Fennec Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Short-Term Debt Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fennec Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fennec Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Fennec Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (TSX:FRX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Short-Term Debt
Comparable Companies
NEOE:CYBN TSX:MDNA TSXV:NGEN TSX:SVA TSX:EPRX TSXV:ARCH TSX:ONC XCNQ:ACOG XCNQ:METX TSX:TH OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
FENC:USA RV41:Germany
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Website
https://www.fennecpharma.com
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.